A Multi-center, Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Macitentan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms SERENADE
- Sponsors Actelion Pharmaceuticals
- 14 Nov 2019 Planned End Date changed from 18 May 2020 to 31 Dec 2021.
- 14 Nov 2019 Planned primary completion date changed from 18 May 2020 to 30 Apr 2021.
- 31 Aug 2018 Biomarkers information updated